A Case of procainamide and quinidine induced-SLE like syndrome

Minoru Nakamura, Yoshihiro Tsuchiya, Michio Oshima, Hideo Okubo, Toshiyuki Ishimaru, Nobuyuki Shimono

Research output: Contribution to journalArticle

Abstract

A 38 year-old woman was admitted to our hospital complaining of myalgia and muscle weakness in august 1988. Since 1984, she was taking quinidine and procainamide for the treatment of severe arrythmia. On admission, laboratory data revealed pancytopenia, increased erythrocyte sedimentation rate, hypergammaglobulinemia, increase of CPK and aldolase. APTT was prolonged and mixing test was positive, indicating the presence of lupus anticoagulant. LE-test and LE cell were positive and ANF was increased to 5,120 ×. The staining pattern of ANF was mainly homogeneous type. Western blot analysis using purified histone from calf thymus revealed the presence of IgG autoantibodies reacting with H1, H2B and H2A. Other autoantibodies such as PAIgG, anti-ssDNA and anti-cardiolipin antibodies were positive. Drug induced SLE like syndrome was suspected and administration of quinidine and procainamide was stopped soon after the admission. However, SLE like symptoms did not change for the first one month. Then, administration of prednisolone (40mg/day) was initiated. Although prednisolone administration was very effective for subjective symptoms at the beginning, recurrence of SLE like symptoms occured during the tapering of prednisolone. Long term administration of prednisolone for more than 6 months was needed for the control of the symptoms. The association of quinidine and procainamide with SLE-like syndrome is discussed.

Original languageEnglish
Pages (from-to)186-194
Number of pages9
JournalJapanese Journal of Clinical Immunology
Volume14
Issue number2
DOIs
Publication statusPublished - Jan 1 1991

Fingerprint

Procainamide
Quinidine
Prednisolone
Atrial Natriuretic Factor
Autoantibodies
Hypergammaglobulinemia
Lupus Coagulation Inhibitor
Pancytopenia
Fructose-Bisphosphate Aldolase
Cardiolipins
Blood Sedimentation
Myalgia
Muscle Weakness
Histones
Thymus Gland
Cardiac Arrhythmias
Anti-Idiotypic Antibodies
Neutrophils
Immunoglobulin G
Western Blotting

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

A Case of procainamide and quinidine induced-SLE like syndrome. / Nakamura, Minoru; Tsuchiya, Yoshihiro; Oshima, Michio; Okubo, Hideo; Ishimaru, Toshiyuki; Shimono, Nobuyuki.

In: Japanese Journal of Clinical Immunology, Vol. 14, No. 2, 01.01.1991, p. 186-194.

Research output: Contribution to journalArticle

Nakamura, M, Tsuchiya, Y, Oshima, M, Okubo, H, Ishimaru, T & Shimono, N 1991, 'A Case of procainamide and quinidine induced-SLE like syndrome', Japanese Journal of Clinical Immunology, vol. 14, no. 2, pp. 186-194. https://doi.org/10.2177/jsci.14.186
Nakamura, Minoru ; Tsuchiya, Yoshihiro ; Oshima, Michio ; Okubo, Hideo ; Ishimaru, Toshiyuki ; Shimono, Nobuyuki. / A Case of procainamide and quinidine induced-SLE like syndrome. In: Japanese Journal of Clinical Immunology. 1991 ; Vol. 14, No. 2. pp. 186-194.
@article{5f3c8f4705364e6fa8da5ca0b555fd20,
title = "A Case of procainamide and quinidine induced-SLE like syndrome",
abstract = "A 38 year-old woman was admitted to our hospital complaining of myalgia and muscle weakness in august 1988. Since 1984, she was taking quinidine and procainamide for the treatment of severe arrythmia. On admission, laboratory data revealed pancytopenia, increased erythrocyte sedimentation rate, hypergammaglobulinemia, increase of CPK and aldolase. APTT was prolonged and mixing test was positive, indicating the presence of lupus anticoagulant. LE-test and LE cell were positive and ANF was increased to 5,120 ×. The staining pattern of ANF was mainly homogeneous type. Western blot analysis using purified histone from calf thymus revealed the presence of IgG autoantibodies reacting with H1, H2B and H2A. Other autoantibodies such as PAIgG, anti-ssDNA and anti-cardiolipin antibodies were positive. Drug induced SLE like syndrome was suspected and administration of quinidine and procainamide was stopped soon after the admission. However, SLE like symptoms did not change for the first one month. Then, administration of prednisolone (40mg/day) was initiated. Although prednisolone administration was very effective for subjective symptoms at the beginning, recurrence of SLE like symptoms occured during the tapering of prednisolone. Long term administration of prednisolone for more than 6 months was needed for the control of the symptoms. The association of quinidine and procainamide with SLE-like syndrome is discussed.",
author = "Minoru Nakamura and Yoshihiro Tsuchiya and Michio Oshima and Hideo Okubo and Toshiyuki Ishimaru and Nobuyuki Shimono",
year = "1991",
month = "1",
day = "1",
doi = "10.2177/jsci.14.186",
language = "English",
volume = "14",
pages = "186--194",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - A Case of procainamide and quinidine induced-SLE like syndrome

AU - Nakamura, Minoru

AU - Tsuchiya, Yoshihiro

AU - Oshima, Michio

AU - Okubo, Hideo

AU - Ishimaru, Toshiyuki

AU - Shimono, Nobuyuki

PY - 1991/1/1

Y1 - 1991/1/1

N2 - A 38 year-old woman was admitted to our hospital complaining of myalgia and muscle weakness in august 1988. Since 1984, she was taking quinidine and procainamide for the treatment of severe arrythmia. On admission, laboratory data revealed pancytopenia, increased erythrocyte sedimentation rate, hypergammaglobulinemia, increase of CPK and aldolase. APTT was prolonged and mixing test was positive, indicating the presence of lupus anticoagulant. LE-test and LE cell were positive and ANF was increased to 5,120 ×. The staining pattern of ANF was mainly homogeneous type. Western blot analysis using purified histone from calf thymus revealed the presence of IgG autoantibodies reacting with H1, H2B and H2A. Other autoantibodies such as PAIgG, anti-ssDNA and anti-cardiolipin antibodies were positive. Drug induced SLE like syndrome was suspected and administration of quinidine and procainamide was stopped soon after the admission. However, SLE like symptoms did not change for the first one month. Then, administration of prednisolone (40mg/day) was initiated. Although prednisolone administration was very effective for subjective symptoms at the beginning, recurrence of SLE like symptoms occured during the tapering of prednisolone. Long term administration of prednisolone for more than 6 months was needed for the control of the symptoms. The association of quinidine and procainamide with SLE-like syndrome is discussed.

AB - A 38 year-old woman was admitted to our hospital complaining of myalgia and muscle weakness in august 1988. Since 1984, she was taking quinidine and procainamide for the treatment of severe arrythmia. On admission, laboratory data revealed pancytopenia, increased erythrocyte sedimentation rate, hypergammaglobulinemia, increase of CPK and aldolase. APTT was prolonged and mixing test was positive, indicating the presence of lupus anticoagulant. LE-test and LE cell were positive and ANF was increased to 5,120 ×. The staining pattern of ANF was mainly homogeneous type. Western blot analysis using purified histone from calf thymus revealed the presence of IgG autoantibodies reacting with H1, H2B and H2A. Other autoantibodies such as PAIgG, anti-ssDNA and anti-cardiolipin antibodies were positive. Drug induced SLE like syndrome was suspected and administration of quinidine and procainamide was stopped soon after the admission. However, SLE like symptoms did not change for the first one month. Then, administration of prednisolone (40mg/day) was initiated. Although prednisolone administration was very effective for subjective symptoms at the beginning, recurrence of SLE like symptoms occured during the tapering of prednisolone. Long term administration of prednisolone for more than 6 months was needed for the control of the symptoms. The association of quinidine and procainamide with SLE-like syndrome is discussed.

UR - http://www.scopus.com/inward/record.url?scp=85007857395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007857395&partnerID=8YFLogxK

U2 - 10.2177/jsci.14.186

DO - 10.2177/jsci.14.186

M3 - Article

AN - SCOPUS:85007857395

VL - 14

SP - 186

EP - 194

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 2

ER -